🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,121 results for “ACE” Clear

  1. BI 456906, Placebo, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906

    Boehringer Ingelheim International GmbH

    Obesity, Diabetes mellitus type II

    phase 3 small molecule active

    1 trial

  2. BI 764198, Placebo matching BI 764198

    Boehringer Ingelheim International GmbH

    Focal segmental glomerulosclerosis

    phase 3 small molecule active

    1 trial

  3. BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient., BIIB059

    Biogen Idec Ltd

    Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  4. BIIB059, BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient

    Biogen Idec Ltd

    systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  5. BIIB059, Biib059 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of biib059 drug product minus the active ingredient

    Biogen Idec Ltd

    systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  6. BIIB059, Biib059 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of biib059 drug product minus the active ingredient.

    Biogen Idec Ltd

    Systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  7. BIIB067, PL1, Solution for injection, Intrathecal use. [Placebo]

    Biogen Idec Ltd

    Amyotrophic Lateral Sclerosis (ALS) associated with SOD1 gene mutation

    phase 3 small molecule active

    1 trial

  8. BT-001

    CATALYST PHARMACEUTICALS, INC.

    Type2 Diabetes

    phase 3 other terminated

    1 trial

  9. BYL719, BYL719, Placebo to BYL719 125 mg film-coated tablets, Placebo to BYL719 200 mg film-coated tablets, Placebo to BYL719 50 mg film-coated tablets, BYL719, BYL719, BYL719

    Novartis Ophthalmics Europe

    lymphatic malformations associated with PIK3CA mutation

    phase 3 small molecule active

    1 trial

  10. Baxdrostat, Baxdrostat Placebo

    AstraZeneca AB

    Resistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated dose, including a diuretic.

    phase 3 small molecule active

    1 trial

  11. Baxdrostat, Baxdrostat Placebo, Baxdrostat

    AstraZeneca AB

    Uncontrolled hypertension (uTHN) defined as blood pressure that remains higher than goal levels despite patients being treated with 2 anti-hypertensive agents, including a diuretic. Resistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated dose, including a diuretic.

    phase 3 small molecule active

    1 trial

  12. Baxdrostat, Baxdrostat, Baxdrostat Placebo

    AstraZeneca AB

    Primary Aldosteronism defined by excess aldosterone secretion

    phase 3 small molecule active

    1 trial

  13. Baxdrostat, Baxdrostat, Baxdrostat, Forxiga 10 mg film-coated tablets, Baxdrostat placebo

    AstraZeneca AB

    Chronic kidney disease (CKD) and hypertension.

    phase 3 small molecule active

    1 trial

  14. Baxdrostat, Forxiga 10 mg film-coated tablets, Baxdrostat, Baxdrostat placebo

    AstraZeneca AB

    Chronic kidney disease (CKD) and hypertension.

    phase 3 small molecule active

    1 trial

  15. Beltavac Polymerized placebo. It is a saline solution without the allergenic extract, BELTAVAC with polymerized extract From Dermatophagoides

    Pharma Mar S.A.

    Allergic rhinoconjunctivitis due to exposure of house dust mites

    phase 3 small molecule active

    1 trial

  16. Bemnifosbuvir (BEM)

    Atea Pharmaceuticals

    Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)

    phase 3 small molecule completed

    1 trial

  17. Bemnifosbuvir-Ruzasvir

    Atea Pharmaceuticals

    HEPATITIS C VIRUS CHRONIC INFECTION

    phase 3 small molecule active

    1 trial

  18. Bemnifosbuvir-Ruzasvir (BEM/RZR)

    Atea Pharmaceuticals

    HEPATITIS C VIRUS CHRONIC INFECTION

    phase 3 small molecule active

    1 trial

  19. Bemnifosbuvir/Ruzasvir Fixed Dose Combination (FDC), Sofosbuvir / Velpatasvir

    Atea Pharmaceuticals

    Chronic Hepatitis C Virus (HCV) Infection

    phase 3 small molecule active

    1 trial

  20. Benlysta 200 mg solution for injection in pre-filled syringe., Placebo for Belimumab Solution for Injection, 200 mg/mL. The placebo for Belimumab Solution for Injection, 200 mg/mL is provided as a sterile solution for subcutaneous (SC) injection in single-use prefilled syringes.

    GlaxoSmithKline Biologicals S.A.

    Lung Diseases, Interstitial

    phase 3 small molecule active

    1 trial

  21. Benralizumab Placebo for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (APFS) for subcutaneous injection. Please refer to the IMPD documentation enclosed., Placebo, Fasenra 30 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Hypereosinophilic Syndrome (HES)

    phase 3 small molecule active

    1 trial

  22. Bexicaserin, LP352 (bexicaserin) Placebo Oral Solution

    Pharma Mar S.A.

    Dravet Syndrome

    phase 3 small molecule active

    1 trial

  23. Bexotegrast, Placebo matching PLN-74809

    PLIANT THERAPEUTICS, INC.

    Idiopathic pulmonary fibrosis (IPF)

    phase 3 small molecule active

    1 trial

  24. Bilateral Nucleus Accumbens DBS (Suzhou Sceneray)

    China SXT Pharmaceuticals

    Obsessive Compulsive Disorder

    phase 3 other terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources